Abstract |
Multiple factors differentially influence treatment decisions in the first line treatment of recurrent/metastatic HNSCC. The EORTC Young investigator group launched a survey among treating physicians to explore the main influencing factors for treatment stratification. The questionnaire was posted as a web-survey link from May to August 2020. Next to defining the factors that mostly influence therapeutic decision the survey was complemented by a clinical case discussion of five patient cases. A total of 118 responses from 19 countries were collected. The key factors identified to guide treatment decision were performance status, PD-L1 Expression, time from last systemic treatment above or below 6 months, and disease burden. Prospective evaluation of patient characteristics and additional potential predictive biomarkers for novel treatment options remains an important question to stratify personalized treatment for RM HNSCC.
|
Authors | Konrad Klinghammer, Luigi Lorini, Daan Nevens, Christian Simon, Jean-Pascal Machiels, Paolo Bossi |
Journal | Frontiers in oncology
(Front Oncol)
Vol. 12
Pg. 730785
( 2022)
ISSN: 2234-943X [Print] Switzerland |
PMID | 35155222
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Klinghammer, Lorini, Nevens, Simon, Machiels and Bossi. |